71 related articles for article (PubMed ID: 9548492)
1. TCR vaccines for active immunotherapy of T cell malignancies.
Okada CY; Wong CP; Denney DW; Levy R
J Immunol; 1997 Dec; 159(11):5516-27. PubMed ID: 9548492
[TBL] [Abstract][Full Text] [Related]
2. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
Wong CP; Okada CY; Levy R
J Immunol; 1999 Feb; 162(4):2251-8. PubMed ID: 9973501
[TBL] [Abstract][Full Text] [Related]
3. Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma.
Wong CP; Levy R
Cancer Res; 2000 May; 60(10):2689-95. PubMed ID: 10825142
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant IL-15 does not enhance the efficacy of tumor cell lysate-pulsed dendritic cell vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
Cancer Immunol Immunother; 2006 Apr; 55(4):420-32. PubMed ID: 16025264
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma.
Gatza E; Okada CY
J Immunol; 2002 Nov; 169(9):5227-35. PubMed ID: 12391241
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with DNA encoding a single-chain TCR fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma.
Thirdborough SM; Radcliffe JN; Friedmann PS; Stevenson FK
Cancer Res; 2002 Mar; 62(6):1757-60. PubMed ID: 11912151
[TBL] [Abstract][Full Text] [Related]
7. Binding of radiation leukemia viruses to a thymic lymphoma involves some class I molecules on the T cell as well as the T cell receptor complex.
O'Neill HC
J Mol Cell Immunol; 1989; 4(4):213-23. PubMed ID: 2558669
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help.
Savelyeva N; King CA; Vitetta ES; Stevenson FK
Proc Natl Acad Sci U S A; 2005 Aug; 102(31):10987-92. PubMed ID: 16037207
[TBL] [Abstract][Full Text] [Related]
9. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
10. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
[TBL] [Abstract][Full Text] [Related]
11. TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection.
Lambert SL; Okada CY; Levy R
J Immunol; 2004 Jan; 172(2):929-36. PubMed ID: 14707065
[TBL] [Abstract][Full Text] [Related]
12. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells.
Liu X; Peralta EA; Ellenhorn JD; Diamond DJ
Cancer Res; 2000 Feb; 60(3):693-701. PubMed ID: 10676655
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes.
Bettahi I; Dasgupta G; Renaudet O; Chentoufi AA; Zhang X; Carpenter D; Yoon S; Dumy P; BenMohamed L
Cancer Immunol Immunother; 2009 Feb; 58(2):187-200. PubMed ID: 18584174
[TBL] [Abstract][Full Text] [Related]
14. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
[TBL] [Abstract][Full Text] [Related]
15. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
17. Defective CD8+ T cell activation and cytolytic function in the absence of LFA-1 cannot be restored by increased TCR signaling.
Shier P; Ngo K; Fung-Leung WP
J Immunol; 1999 Nov; 163(9):4826-32. PubMed ID: 10528183
[TBL] [Abstract][Full Text] [Related]
18. Radiation leukemia virus-induced T-cell lymphomas with common T-cell receptor variable region structure and similar binding specificity for retrovirus.
O'Neill HC
Leukemia; 1991 Nov; 5(11):921-7. PubMed ID: 1961032
[TBL] [Abstract][Full Text] [Related]
19. Anti-idiotypic regulatory responses induced by vaccination with DNA encoding murine TCR Valpha5 and Vbeta2.
Wu Y; Zhang Y; Xu X; Lv P; Gao X
Cell Mol Immunol; 2007 Aug; 4(4):287-93. PubMed ID: 17764619
[TBL] [Abstract][Full Text] [Related]
20. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
